Ondine Biomedical’s Steriwave Technology Gains Recognition for Reducing Surgical Infections

Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an update.

Ondine Biomedical Inc. announced that the Mid Yorkshire Teaching NHS Trust has been shortlisted for the HSJ Patient Safety Awards due to the successful use of Ondine’s Steriwave nasal decolonization technology, which significantly reduced surgical site infections by 71% in hip and knee surgeries. This recognition highlights the effectiveness of Steriwave in combating healthcare-associated infections without contributing to antimicrobial resistance, potentially enhancing Ondine’s position in the healthcare industry and sparking interest across NHS hospitals.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system, Steriwave, approved in several countries and undergoing clinical trials in the US.

Average Trading Volume: 156,113

Technical Sentiment Signal: Buy

Current Market Cap: £46.54M

For a thorough assessment of OBI stock, go to TipRanks’ Stock Analysis page.